Enliven Therapeutics’ Chief Medical Officer Disposes of 5,000 Shares While Maintaining Substantial Equity Position

Key Points

• The Chief Medical Officer, Helen Collins, sold 5,000 shares of common stock for roughly $199,000 on May 18, 2026, at an average price of about $39.79 per share.

• The transaction represented 16.67% of her direct holdings, leaving her with approximately 25,000 shares, which equals about 0.041% of the outstanding shares.

• The sale involved only direct ownership; the shares were obtained by exercising stock options and then sold on the open market.

Helen Louise Collins, Chief Medical Officer at Enliven Therapeutics (NASDAQ:ELVN) disclosed the transaction in an SEC Form 4 filing.

Transaction summary

MetricValueShares sold (direct)5,000Transaction value$199,000Post-transaction shares (direct)25,000Post-transaction value (direct ownership)~$994,750

Values are based on the SEC Form 4 weighted‑average purchase price of $39.79.

Key Questions

• What was the structure and timing of the transaction?
  The sale consisted of an option exercise for 5,000 shares, immediately followed by an open‑market sale at approximately $39.79 per share on May 18, 2026.
• How does this sale affect Collins’ overall exposure to Enliven Therapeutics?
  Although her direct common‑stock position fell to 25,000 shares, she still holds a substantial unexercised option grant of 126,268 shares, preserving significant upside potential.
• Was the transaction size or frequency typical?
  Recent months included larger administrative sales (e.g., 45,000 and 40,000‑share trades). The 5,000‑share sale is modest and reflects the reduced share balance after those prior dispositions.
• What is the current valuation and market performance context?
  As of May 18, 2026, the stock closed at $39.63, marking a one‑year total return of 135.2% and a market capitalization of $2.53 billion; Collins’ post‑sale stake is valued at roughly $995,000.

Company Overview

As of the market close on May 18, 2026, the share price was $39.63, giving the company a market cap of $2.53 billion. Net income over the trailing twelve months was a loss of $98.78 million, with a one‑year price change of 135.2%.

Enliven Therapeutics develops small‑molecule kinase inhibitors, focusing on ELVN‑001 for chronic myeloid leukemia and ELVN‑002 for HER2‑mutant cancers, both in Phase 1 trials.

The company operates a clinical‑stage biopharmaceutical model, aiming to discover and advance proprietary oncology therapies for future commercialization or partnerships. Its strategy targets oncology specialists, research hospitals, and pharmaceutical partners addressing unmet cancer needs.

Enliven Therapeutics is a clinical‑stage biotechnology firm dedicated to creating targeted cancer treatments. Its pipeline of kinase inhibitors is designed to fill gaps in current oncology therapies and offer differentiated prospects.

What This Transaction Means for Investors

The sale of 5,000 shares by Chief Medical Officer Helen Collins on May 18 is not a cause for investor alarm. The transaction was conducted under a Rule 10b5‑1 plan adopted in October 2025, a common mechanism for insiders to trade without appearing to act on material information.

Collins continues to retain a sizable equity interest exceeding 150,000 shares, comprising vested options and restricted stock units, indicating a continued stake in the company’s long‑term performance. The sale occurred while the stock was trading near its recent highs, though the price has since moderated from its April 17 peak of $48.53.

Enliven Therapeutics has yet to generate revenue and reported a net loss of $23.6 million for the first quarter, down from $28.5 million a year earlier. At the end of the quarter, the company held $452.4 million in cash, cash equivalents, and marketable securities, which it expects to fund operations through the first half of 2029.

Source link